Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
Go back to Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales| CYTOKINETICS (NASDAQ: CYTK) | Delayed: 69.92 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $69.92 | 52 Week High | $13.18 | |||
| Open | $69.92 | 52 Week Low | $6.00 | |||
| Day High | $69.92 | P/E | N/A | |||
| Day Low | $69.92 | EPS | $-1.24 | |||
| Volume | 1,850 | |||||
